Literature DB >> 10456038

Medical and surgical treatment of Parkinson's disease. Strategies to slow symptom progression and improve quality of life.

S C Conley1, J T Kirchner.   

Abstract

Despite new medical and surgical therapy, mortality rates for Parkinson's disease remain unchanged. Nevertheless, symptom progression can be slowed and quality of life improved with current methods of treatment. Levodopa is the most effective drug for Parkinson's disease, but its long-term use is associated with significant motor complications. Dopamine agonists hold promise because of more sustained stimulation of dopamine receptors and possibly an antioxidant effect. Selegiline, amantadine, and anticholinergics are still used but must be employed with caution in the elderly. COMT inhibitors may be useful adjuncts to levodopa therapy but are plagued with serious adverse effects. Goals of therapy in patients less than 60 years of age include sparing levodopa therapy and providing neuroprotection. For patients 60 years and older, goals include maintaining cognitive status and treating symptoms. Surgical treatment includes globus pallidus internal-segment pallidotomy, deep brain stimulation, and fetal nigral transplantation. These hold promise for the future.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10456038     DOI: 10.3810/pgm.1999.08.648

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  3 in total

Review 1.  Tolcapone: a review of its use in the management of Parkinson's disease.

Authors:  Gillian M Keating; Katherine A Lyseng-Williamson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  Cabergoline : a review of its use in the treatment of Parkinson's disease.

Authors:  Monique P Curran; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 3.  Genes Implicated in Familial Parkinson's Disease Provide a Dual Picture of Nigral Dopaminergic Neurodegeneration with Mitochondria Taking Center Stage.

Authors:  Rafael Franco; Rafael Rivas-Santisteban; Gemma Navarro; Annalisa Pinna; Irene Reyes-Resina
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.